May 29, 2024 Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
May 29, 2024 Obtaining the status of Associate Partner within IPCEI Med4Cure
Read More
May 28, 2024 Conclusion of funding agreement with the National Centre for Research and Development
Read More
May 23, 2024 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
May 15, 2024 Ryvu Therapeutics S.A. Q1 2024 Financial Report
Read More
May 14, 2024 Preclinical and clinical data on RVU120 to be presented at the 2024 European Hematology Association Congress
Read More
April 10, 2024 Posters on preclinical data on RVU120 and Synthetic Lethality Programs presented at the 2024 AACR Annual Meeting
Read More
March 29, 2024 Conclusion of an agreement in the area of operational execution of RVU120 Phase II clinical trial in myelofibrosis
Read More
March 27, 2024 Ryvu project recommended for funding by the Polish Agency for Enterprise Development
Read More
March 8, 2024 Correction of the current report No. 12/2024 of March 6, 2024 – correction of obvious typographical error
Read More
March 6, 2024 Fulfillment of conditions for the disbursement of the Tranche A of financing from the European Investment Bank
Read More
March 6, 2024 Preclinical data on RVU120 and Synthetic Lethality Programs to be presented at the 2024 AACR Annual Meeting
Read More
February 14, 2024 Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS
Read More
February 9, 2024 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
February 7, 2024 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
February 5, 2024 Achievement of the second milestone under license agreement with Exelixis Inc.
Read More
February 5, 2024 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
January 31, 2024 Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax
Read More
January 31, 2024 Registration of series K subscription warrants of the Company with the National Depository for Securities
Read More
January 18, 2024 Publication dates for periodic reports in 2024
Read More
Posts navigation
